Cardiovascular proteomics: past, present, and future.

Cardiovascular proteomics: past, present, and future. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cardiovascular proteomics: past, present, and future. Abstract Text:

Melanie Y White,Jennifer E Van Eyk,

With cardiovascular (CV)-related disorders accounting for the highest mortality rates in the world, affecting the quantity and quality of life of patients and creating an economic burden of prolonged therapeutic intervention, there is great significance in understanding the cellular and molecular alterations that influence the progression of these pathologies. The cellular genotype is regulated by the DNA component, whilst the cellular phenotype is influenced by the protein complement. By improving the understanding of the molecular mechanisms that influence the protein profile, the pathologies that influence the intrinsic functions of the CV system may be detected earlier or managed more efficiently. This is achievable with technologies encompassed by 'proteomics.' Proteomic investigations of CV diseases, including dilated cardiomyopathy (DCM), atherosclerosis, and ischemia/reperfusion (I/R) injury, have identified candidate proteins altered with the pathologic states, complementing past biochemical and physiologic observations. Whilst proteomics is still a relatively new discipline to be applied to the basic scientific investigation of CV diseases, it is emerging as a technique to screen for potential biomarkers in both tissues/cells and biologic fluids (biofluids), as well as to identify the targets of existing therapeutics. By enabling the separation of complex mixtures over numerous dimensions, exploiting the intrinsic properties of proteins, including charge state, molecular mass, and hydrophobicity, in addition to cellular location, the discrete alterations within the cell may be resolved. Proteomics has shown alterations to myofilament proteins including troponin I and myosin light chain, correlating with the reduction in contractility in the myocardium from DCM and I/R. The diverse cell types that coalesce to induce atherosclerotic plaque formation have been investigated both collectively and individually to elucidate the influence of the modifications to single cell types on the developing plaque as a whole. Proteomics has also been used to observe changes to biofluids occurring with these pathologies, a new potential link between basic science and clinical applications. The development of CV proteomics has helped to identify a number of possible protein candidates, and offers the potential to treat and diagnose CV disease more effectively in the future.

Cardiovascular proteomics: past, present, and future. Publishing Authors By Initials

MY White,JE Van Eyk,

For similar cardiovascular diseases: vascular diseases: reperfusion injury research abstracts see: cardiovascular diseases: vascular diseases: reperfusion injury research

PUBMED ID PMID:

MEDLINE DATE:

Cardiovascular proteomics: past, present, and future. Journal Published:

PUBLICATION TYPE: Review

Journal: Molecular diagnosis & therapy

VOLUME: 11

Page Numbers: 83-95

Journal Abbreviation:

ISSN: 1177-1062

DAY: 3

MONTH: 12

YEAR: 2007

Cardiovascular proteomics: past, present, and future. Information

Number of References: 136

LANGUAGE: eng

NlmUniqueID: 101264260

Cardiovascular proteomics: past, present, and future. Keywords Mesh Terms:

KEYWORDS: Reperfusion Injury

MESH TERMS: metabolism

Chemical & Substance for Abstract: Cardiovascular proteomics: past, present, and future. Information

Substance Name: Proteome

Registry Number: 0

Grant and Affiliation Information for Cardiovascular proteomics: past, present, and future.

AFFILIATION: Department of Medicine, Johns Hopkins University, Baltimore, Maryland 21224, USA.

Country: New Zealand

AGENCY: United States NHLBI

GRANT: P01HL081427

ACRONYM: HL

MEDLINETA: Mol Diagn Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cardiovascular proteomics: past, present, and future Related Publications

• A proteomic primer for the clinician.
• A rapid, economical, and reproducible method for human serum delipidation and albumin and IgG removal for proteomic analysis.
• Cardiovascular proteomics: past, present, and future.
• Expanding the subproteome of the inner mitochondria using protein separation technologies: one- and two-dimensional liquid chromatography and two-dimensional gel electrophoresis.
• Heart disease, clinical proteomics and mass spectrometry.
• Is familial hemiplegic migraine a hereditary form of basilar migraine?
• Optimization of cardiac troponin I pull-down by IDM affinity beads and SELDI.
• Optimization of paper bridge loading for 2-DE analysis in the basic pH region: application to the mitochondrial subproteome.
• Proteomic alterations in heat shock protein 27 and identification of phosphoproteins in ascending aortic aneurysm associated with bicuspid and tricuspid aortic valve.
• Proteomics of the aqueous humor in healthy New Zealand rabbits.